Kornimate/medical-research-clean huggingface dataset:
effect of different desensitizing agents on post-bleaching hypersensitivity and shade stability

Conditions: Tooth Hypersensitivity

Summary: this study compared the effect of four different desensitizing agents on shade stability and dental hypersensitivity following dental bleaching procedure. the follow-up periods ranged from 24 hours to 1 year.

this study was conducted to assess the effectiveness of 4 different desensitizing agents used after dental bleaching regarding dental hypersensitivity and shade stability. it was a double-blinded randomized clinical trial. the ethical approval was obtained in may 2020 by the research ethics committee an institutional review board, faculty of dentistry, ain shams university (fdasu-rec). the number of patients was determined according to g-power program with a power (1-β error) of 0.8 (power = 80%), and 95% confidence level (α = 0.05) using a two-sided hypothesis test. according to sample size calculation, 40 patients were needed for this study (n=10 per group). patients were selected according to inclusion and exclusion criteria and were randomly assigned into 4 groups according to the desensitizing agent used. the 4 desensitizing agents were: after whitening mousse, mi paste plus, hydroxyapatite and fluoride (reminpro) and pamam. patients signed an informed consent and received a detailed explanation of the study procedures. baseline dental shade was recorded using vita easy-shade spectrophotometer and vita classical shade guide. baseline sensitivity was assessed and recorded using a vas. all patients received dental bleaching using in-office chemically activated power whitening yf (whitesmile, germany) followed by a desensitizing procedure using the desensitizing agent assigned to the specific experimental group. dental shade and dental hypersensitivity was assessed at different follow-up appointments; 24-hours, 3 days, 1 week, 1 month, 3 months, 6 months, 9 months and 1 year following the procedures. assessment of these variables at follow-up appointments was performed by 2 external assessors, and patients were blinded to the type desensitizing agent used.

Eligibility criteria:
inclusion criteria: * participants with their entire upper and lower teeth, from right first premolar to left first premolar, present and sound, without restorations or periodontal disease. * the participants had low-caries index scores. * participants had teeth with a vita-color shade of a2 or darker. * cooperative behavior patient and medically free. * patient ages between 18 to 40 years old exclusion criteria: * serious medically compromised patients. * smoking, alcoholism. * hypersensitivity to the agents used in the study. * lactating, pregnant patients. * patients with serious oral diseases, as acute necrotizing gingivitis, acute gingiva stomatitis, or those undergoing orthodontic treatment. * patients with dental enamel cracks. * patients who've had previous bleaching treatments

Keywords: dental bleaching shade stability
thoracoscopic localization of pulmonary nodules using direct intracavitary thoracoscopic ultrasound

Conditions: Lung Cancer

Summary: pulmonary nodules are one of the most common thoracic radiographic abnormalities. they are usually found accidentally as discrete well emarginated pulmonary lesions found within the lung parenchyma during a routine chest x-ray. pulmonary nodules are usually asymptomatic. most solitary lung nodules are benign; however these nodules can represent early stage lung cancer. the identification of malignant pulmonary nodules is important because they represent a potential form of curable lung malignancy. every lung nodule should therefore be investigated for the possibility of malignancy. ultrasound has been beneficial in almost all medical and surgical specialities. the idea of using ultrasound during vats has emerged from its use in laparoscopic procedures. few studies have investigated the use intracavitary ultrasound for localizing pulmonary nodules. the sensitivity of ultrasound detecting pulmonary nodules is high (92%). in some studies, ultrasound could detect all pulmonary nodules detected by high resolution ct. it has also been shown to be able to locate nodules not visualized on spiral ct. the use of intracavitary ultrasound has been suggested by many authors as a safe and effective method for localizing hard to find nodules. it is a real time technique with no associated complications, low cost, and has the potential to save operative time. most importantly, it may be able to prevent conversion of vats to open operations in cases where nodules are not visualizable or locatable using vats techniques. the use of intracavitary us as a localization method by surgeons intra-operatively could lead to better identification of nodules. also, this technique could avoid performing multiple procedures on patients (ct guided targeting followed by surgery) and therefore is more cost-efficient. if proven accurate, surgeon-performed intracavitary ultrasound could be used routinely during vats procedures, increasing the chances of finding and localizing pulmonary nodules using minimally invasive techniques.


Eligibility criteria:
inclusion criteria: * all patients with ct identified pulmonary nodules not deemed to be visualizable during vats who are candidates for vats resection. exclusion criteria: * inability to consent for the study. * patients less than 18 years old. * patients with pulmonary nodules easily located during vats. * patients with tumours extending to visceral pleura or chest wall. * patients who have chest anatomy precluding vats resection.

Keywords: lung cancer intracavitary ultrasound pulmonary nodules vats procedures
comparison of a locally produced rutf with a commercial rutf in the treatment of sam

Conditions: Malnutrition; Children; Treatment

Summary: in order to make cambodia independent from importing a product for the treatment and prevention of malnutrition, unicef, dfptq fisheries administration and ird have started a collaboration for the development of a range of products for the treatment and prevention of malnutrition. to reduce costs of the product, and to adapt the taste to local circumstances, the protein source of the usual rutf (milk powder) has been changed to fish (trey riel). the main objective of this sub-study is to test the efficacy of the newly developed rutf on the recovery of children suffering from severe acute malnutrition. as comparison, the current treatment of sam with bp-100 will be used.


Eligibility criteria:
inclusion criteria: * discharged from hospital after admission for sam * whz \<2.8 z-score or muac\<11.5 cm * no complications * passing the appetite test exclusion criteria: * \<6 mo of age * complications related to sam
acetaminophen or fluvastatin compared to placebo on the transient post-dose symptoms (pds) following an intravenous (i.v.) infusion of a single dose of zoledronic acid 5mg, in post-menopausal women with low bone mass

Conditions: Osteoporosis

Summary: this study will evaluate the efficacy of acetaminophen or fluvastatin in reducing the rate of occurrence and the severity of post dose symptoms that may occur during the 3 day period following a zoledronic acid infusion in post menopausal women with low bone mass.


Eligibility criteria:
inclusion criteria: 1. postmenopausal women greater than or equal to 45 and less than or equal to 79 years of age at randomization 2. women who are clinically indicated for treatment with bisphosphonates for osteopenia or osteoporosis with a documented central (spine or hip) bone mineral density t score less than or equal to 1.5 exclusion criteria: 1. any prior treatment with intravenous bisphosphonates 2. oral treatment with bisphosphonates for more than 8 weeks or within 6 months prior to the screening visit 3. patients who are taking, and are unwilling or unable to stop taking, certain medications 4. patients who require anticoagulant therapy 5. patients with a known hypersensitivity to ibuprofen, acet, bisphosphonates, statins or with allergies manifested by attacks of asthma, urticaria or acute rhinitis following 6. proteinuria (protein detected on a urine dipstick) greater than or equal to 2+ at screening 7. protocol specific laboratory values that fall out of range for this study 8. ongoing infection (oral body temperature greater than or equal to 37.5c (99.5°f),chronic febrile disease or fever of unknown origin at screening or randomization 9. active dental infection, unhealed dental extraction or planned oral surgery within 3 months after randomization 10. history of iritis, uveitis or chronic conjunctivitis 11. history of hypoparathyroidism, hyperparathyroidism or paget's disease 12. partial or total removal of parathyroid or thyroid gland 13. history of malignancy of any organ system, treated or untreated, within the past 1 year whether or not there is evidence of local recurrence or metastases, with the exception of localized basal cell carcinoma of the skin 14. treatment with an investigational drug within the previous 30 days of screening 15. patients with any medical or psychiatric condition which, in the opinion of the principal investigator, would preclude the participant from adhering to the protocol or completing the trial per protocol, or any patient who the principal investigator thinks should not participate in the study for any reason, including current drug or alcohol abuse other protocol-defined inclusion/exclusion criteria may apply

Keywords: zoledronic acid post dose symptoms transient acetaminophen fluvastatin
blood propofol concentrations in children during spinal surgery

Conditions: Spine Deformities; Idiopathic Scoliosis; Neuromuscular Dystrophy

Summary: during major spinal surgery evoked potential monitoring is performed to detect spinal cord damage. intra-venous anaesthesia is the preferred anaesthetic technique because volatile anaesthetic agents supress the evoked potentials. total intra-venous anaesthesia (tiva) with propofol is commonly administered as a target controlled infusion (tci). the tci is an automated drug delivery system which administers propofol to achieve a desired blood concentration, based on an in built pharmaco-kinetic data (tci model) derived from previous studies. the tci model also provides a real time predicted blood concentration to facilitate the anaesthetist to adjust the target concentration of propofol. the tci algorithm is based on pharmaco-kinetic data derived from previous studies in a relatively small number of patients, by a "best fit" relationship between blood levels, infusion rates and other factors (such as age and weight). several factors make it possible for a wide discrepancy between the predicted and the true blood concentrations. this difference can be higher in children compared to adults. also blood loss and administration of large volumes of intravenous fluids can affect the blood concentrations. this study aims to identify the difference between the predicted and true blood concentrations by using pelorus 1500, a bedside blood propofol measurement device, in children undergoing major spinal surgery under tiva.


Eligibility criteria:
inclusion criteria: * children undergoing major spinal surgery under propofol tci * surgery expecting to last more than 3 hours. exclusion criteria: * major hepatic or renal disease

Keywords: children
use of integrated pulmonary index to predict post-operative respiratory adverse events in high risk patients

Conditions: Postoperative Complications

Summary: the capnostream 20p monitor by medtronic is fda-cleared and consists of a monitor which measures real-time respiratory status based on respiratory rate, pulse rate, pulse oximetry (spo2) and end tidal carbon dioxide (etco2) with a disposable nasal canula. the integrated pulmonary index (ipi) is an algorithm driven parameter derived from non-invasive etco2, respiratory rate, pulse rate and spo2. fuzzy logic is used to produce a value from 1-10 with 4 and under requiring intervention and 8-10 representing the normal range. the purpose of this observational study is to determine if the ipi is associated with complications in the immediate postoperative period. the study will enroll approximately 600 patients at 2 centers. clinicians will be blinded to the ipi therefore this device will not be used to guide care in any way.


Eligibility criteria:
inclusion criteria: 18 years or older planned to undergo general anesthesia for surgery exclusion criteria: pregnant inability to consent mechanically ventilated prior to surgery
virtual lifestyle program evaluation during severe acute respiratory syndrome coronavirus 2 (sars-cov-2)

Conditions: Cardiometabolic Syndrome; Weight Loss

Summary: this is a pilot study evaluating an online cardiometabolic and weight loss program which is offered by the wellness institute. the program is 16 weeks and is developed by a multidisciplinary team and delivered by a degreed health professional (health coach) to assist participants in achieving their personal wellness goals. this study will also investigate the impact of coronavirus disease (covid-19) on participants lifestyles and access to lifestyle programs and supports.

the wellness institute is offering a new cardiometabolic and weight loss program. it is a digital behavior change program designed to help clients achieve healthy weight reduction, thereby improving cardiometabolic risk. the target population is overweight or obese individuals at risk for or living with health conditions such as pre-diabetes, diabetes, hypertension and high cholesterol. the purpose of this study is to evaluate the program following a mixed methods quasi-experimental approach using focus groups, questionnaires, and data collected over the 16 week duration of the program. participants will be asked to fill in a set of questionnaires to measure physical activity, diet, sleep and stress at the start and end of the program. other outcomes include changes in body weight, body mass index (bmi), blood pressure, clinical chemistry, and medication intake over the 16 week program. at the end of the program, adherence will be measured though attendance and platform usage and acceptability will be measured by an exit questionnaire and virtual focus groups. this study will investigate the impact of covid-19 on participants lifestyles and access to lifestyle programs and support. the impact of covid-19 will be assessed through a covid-19 questionnaire and virtual focus groups.

Eligibility criteria:
program inclusion criteria: • male or female, aged 18 years or above, have one or more of the following conditions: pre-diabetes, diabetes, high blood pressure, high triglycerides, low hdl, abdominal obesity, and bmi \>25 kg/m2. program exclusion criteria: * female participant who is pregnant, lactating or planning pregnancy during the course of the program. * recent heart attack, stroke, heart surgery, and congestive heart failure. * participants who have unmanaged diabetes, chest pain or difficulty breathing.

Keywords: virtual platform evaluation diet physical activity behavior change sleep stress
study to evaluate the safety and pk of lodient tablet 80/2.5mg in healthy adult volunteers

Conditions: Hypertension

Summary: a randomized, open label, single dose, 2-sequence, 4-period, cross-over phase i clinical trial to compare and evaluate the safety and pharmacokinetics after oral administration of "lodient tablet 80/2.5mg(telmisartan/s-amlodipine)" and "twinsta tablet 80/5mg(telmisartan/amlodipine)" in healthy adult volunteers.

amlodipine is a drug which belongs to calcium channel blockers (ccbs) and is used to treat hypertension. the molecule contains one chiral carbon atom and exists as a racemic mixture. as only the s-enantiomer of amlodipine \[s-amlodipine\] shows the ccb effect and r-amlodipine is responsible for the development of peripheral edema, purifying s-amlodipine can reduce the incidences of peripheral edema and other side effects.

Eligibility criteria:
inclusion criteria: 1. healthy volunteers aged more than 19 years old 2. subject does not have congenital or chronic disease and is without pathologic symptom or finding on medical exam. 3. subject was determined eligible according to the results of clinical laboratory tests like serum test, hematologic test, blood chemistry test, urine test etc. and vital signs, electrocardiography, physical exam etc. performed during the screening exam. 4. 90mmhg≤sbp≤139mmhg and 60mmhg≤dbp≤89mmhg) 5. body mass index (bmi) of 18-30kg/m2 6. willing and able to provide written informed consent exclusion criteria: 1. administration of other drug than can modulate metabolic enzyme within 1 months prior to the scrrening day. 2. volunteers considered not eligible for the clinical trial by the investigator (study doctor) due to reasons including laboratory test results, ecgs, or vital signs 3. continued excessive use of alcohol(alcohol\>21 cups/day) and severe heavy smoker (cigarette \> 20 cigarettes per day) 4. administration of other investigational products within 6 months prior to the first dosing 5. subject with the following conditions in laboratory test : ast(sgot) or alt(sgpt) \> upper normal limit × 1.5 6. subject with whole blood donation within 60 days, component blood donation within 14 days, blood donation within 30 days 7. subject who take a medication that affect to the pharmacokinetics of drug within 10 days 8. subject with decision of non-participation through investigator's review
§ procaine periarticular injections for pain reduction in elderly with osteoarthritis

Conditions: HIP AND KNEE OSTEOARTHRITIS; Geriatric Assessment; Geriatric Depression

Summary: § the goal of this clinical trial is to assess the effect of periarticular procaine injections combined with physical therapy on joint pain in individuals 65 and older suffering from osteoarthritis of the hip or the knee. the main question it aims to answer is: is procaine effective in decreasing joint pain? researchers will compare procaine injections combined with physical therapy to physical therapy only to evaluate whether or not procaine helps decrease joint pain. participants will: undergo procaine periarticular injections and physical therapy assess their symptoms and pain using scales and tests provided

this clinical trial aims to evaluate the safety and efficacy of procaine complex injections in managing pain and improving functional capacity in elderly patients with osteoarthritis in the knee and/or hip. the study enrolled 178 patients aged 65 and older, who were randomly assigned to receive either physical therapy combined with periarticular procaine injections or physical therapy alone. pain levels were assessed using the visual analogue scale (vas), and functional capacity was evaluated using the lequesne index, activities of daily living (adl), instrumental activities of daily living (iadl), and other geriatric assessment tools. results indicated significant pain reduction and functional improvement in the procaine group, highlighting a safe alternative treatment to surgery for older adults with osteoarthritis.

Eligibility criteria:
inclusion criteria: * adults aged 65 and older diagnosed with knee or hip osteoarthritis per the american college of rheumatology criteria. must exhibit radiographic evidence of oa and experience persistent joint pain exclusion criteria: * individuals with alzheimer's, severe depression, cancer, or other severe health conditions, and those with allergies to procaine

Keywords: procaine infiltration geriatric assessment periarticular injections gerovital h3 geriatric depression hip osteoarthritis knee osteoarthritis ana aslan physical therapy activities of daily living (adl) instrumental activities of daily living (iadl)
the role of perirenal fat as predictor in diabetic nephropathy

Conditions: Diabetic

Summary: 1 detect the relationship between perirenal fat thickness (prft) and estimated glomerular filtration rate (egfr) in patients with type 2 diabetes (t2dm). 2)explored the relationship between prf thickness and the onset and progression of albuminuria in patients with diabetes 3)evaluate associations between obesity-related markers with albuminuria and advanced kidney disease in patients with type 2 diabetes mellitus (dm)

diabetic kidney disease (dkd) is the most frequent and severe complication of diabetes mellitus (dm). approximately 40% of patients with diabetes present with proteinuria and renal dysfunction and dkd reportedly account for 50% of newly diagnosed end-stage renal disease (esrd) . metabolic disorders caused by hyperglycemia in dkd can lead to both glucose and lipid metabolism disorders. not only hyperglycemia, many factors including obesity have been reported to be risk factors for diabetic kidney disease . body mass index (bmi) and waist circumference (wc), widely used as obesity indexes, have been proved to aggravate the development of ckd in different subsets of patients , but bmi and wc lack detailed information about the distribution of body fat. body fat is now usually divided into subcutaneous fat and visceral fat according to the anatomical and physiological functions of fat deposition . visceral fat has been thought to be associated with the progression of ckd . recently, new anthropometric and imaging methods have been used to assess visceral fat in clinical practice and research. perirenal fat is a fat pad surrounding the kidneys, located between the renal fibrous membrane and the renal fascia in the retroperitoneal space .prf has been reported to be associated with renal disease in various ways.additionally, it has been proved that renal sinus fat was associated with an increased risk of ckd in general subjects through inflammatory signaling

Eligibility criteria:
inclusion criteria: - patients with t2dm aged 18-70 were included in this study. t2dm was diagnosed according to american diabetes association (ada) ,data collection will obtained over one year from october 2024 to october 2025. clinical diagnosis of alzheimer's disease must be able to swallow tablets exclusion criteria: * b. exclusion criteria: 1. patients with a history of malignancy and surgical trauma. 2. patients diagnosed with nondiabetic renal diseases 3. patients with renal replacement therapy (renal transplant or dialysis patients), renal morphological abnormalities (difference in kidney length between the two cm, solitary kidney or multiple kidneys, congenital kidney abnormalities, polycystic kidney, and hydronephrosis), liver cirrhosis. 4. insulin dependent diabetes 5. thyroid disease
exploratory study of spd489 in adults with major depressive disorder (mdd) as augmentation therapy to an antidepressant

Conditions: Major Depressive Disorder

Summary: to evaluate the efficacy of spd489 when used as augmentation to an antidepressant in the treatment of major depressive disorder (mdd) as measured by mean change in total montgomery-ǻsberg depression rating scale (madrs) scores.


Eligibility criteria:
inclusion criteria: * adults aged 18-55 with a primary diagnosis of nonpsychotic mdd exclusion criteria: * history of non-response to multiple antidepressants